Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: Prognostic value and clinical reliability of the 2004 who classification system

Japanese Journal of Clinical Oncology

Volumn 43, Issue 11, 2013, Pages 1124-1131

  Nishiyama, Naotaka ^a   Kitamura, Hiroshi ^a   Maeda, Toshihiro ^a   Takahashi, Satoshi ^a   Masumori, Naoya ^a   Hasegawa, Tadashi ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1973 WHO classification system; 2004 WHO classification system; Non muscle invasive bladder cancer; Substaging system

Indexed keywords

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RELIABILITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

1973 WHO CLASSIFICATION SYSTEM; 2004 WHO CLASSIFICATION SYSTEM; NON-MUSCLE-INVASIVE BLADDER CANCER; SUBSTAGING SYSTEM;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SAMPLE SIZE; URINARY BLADDER NEOPLASMS; URINE; WORLD HEALTH ORGANIZATION;

EID: 84887054786     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt120     Document Type: Article

References (38)

1. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. Clin Oncol 2006;24:19-27.
2. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 2006;11:28-37.
3. Okajima E, Fujimoto H, Mizutani Y, et al. Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan. Int J Urol 2010;17:905-12.
4. Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 2008;42:95-109.
5. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-42.
6. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010;57:300-9.
7. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57:60-70.
8. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573-83.
9. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-99.
10. Sylvesterx RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
11. van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/ MIB-1) and EORTC risk scores are predictive in primary nonmuscle-invasive bladder cancer. Eur Urol 2010;58:433-41.
12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004.
13. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010;60:1-8.
14. Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol 2010;63:910-5.
15. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002;55:900-5.
16. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-8.
17. Chen Z, Ding W, Xu K, et al. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS One 2012;7:e47199.
18. van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84.
19. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
20. Babjuk M, Oosterlinck W, Sylvester R, et al. European Association of Urology (EAU) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
21. NCCN guidelines version 1.2013 panel members. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Bladder Cancer version 2.2012. www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
22. Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology 2010;76:593-9.
23. van Rhijn BW, van Leenders GJ, Ooms BC, et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010;57:1052-7.
24. Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 2006;175: 1995-2003.
25. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007;51:889-97.
26. Bol MG, Baak JP, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291-4.
27. Okuyama A, Kohri K, Akaza H, et al. The report of clinical statistical studies on registered bladder cancer patients in Japan 1999-2001. Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association. Nihon Hinyokika Gakkai Zassi 2006;97:NP2-31. (in Japanese).
28. Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscleinvasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1515 cases. Am J Clin Pathol 2010;133:788-95.
29. Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008; 54:835-43.
30. Pellucchi F, Freschi M, Ibrahim B, et al. Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J Urol 2011;186:2194-9.
31. Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107:404-8.
32. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000;163:1697-701.
33. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999;86:1035-43.
34. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999;17:3182-87.
35. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J Clin Pathol 2008;61:3-10.
36. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543-48.
37. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995;45:47-53.
38. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800-3.